A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication

Jingwei Wei 1,2,3 · Guoqiang Yang 4 · Xiaohan Hao 1 · Dongsheng Gu 1,2,3 · Yan Tan 4 · Xiaochun Wang 4 · Di Dong 1,2,3 · Shuaitong Zhang 1,2,3 · Le Wang 4 · Hui Zhang 4 · Jie Tian 1,2,3

Received: 20 February 2018 / Revised: 30 April 2018 / Accepted: 29 May 2018 / Published online: 23 July 2018
© The Author(s) 2018

Abstract
Objectives Oxygen 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a significant prognostic biomarker in astrocytomas, especially for temozolomide (TMZ) chemotherapy. This study aimed to preoperatively predict MGMT methylation status based on magnetic resonance imaging (MRI) radiomics and validate its value for evaluation of TMZ chemotherapy effect.

Methods We retrospectively reviewed a cohort of 105 patients with grade II-IV astrocytomas. Radiomic features were extracted from the tumour and peritumoral oedema habitats on contrast-enhanced T1-weighted images, T2-weighted fluid-attenuated inversion recovery images and apparent diffusion coefficient (ADC) maps. The following radiomics analysis was structured in three phases: feature reduction, signature construction and discrimination statistics. A fusion radiomics signature was finally developed using logistic regression modelling. Predictive performance was compared between the radiomics signature, previously reported clinical factors and ADC parameters. Validation was additionally performed on a time-independent cohort (n = 31). The prognostic value of the signature on overall survival for TMZ chemotherapy was explored using Kaplan Meier estimation.

Results The fusion radiomics signature exhibited supreme power for predicting MGMT promoter methylation, with area under the curve values of 0.925 in the training cohort and 0.902 in the validation cohort. Performance of the radiomics signature surpassed that of clinical factors and ADC parameters. Moreover, the radiomics approach successfully divided patients into high-risk and low-risk groups for overall survival after TMZ chemotherapy (p = 0.03).

Conclusions The proposed radiomics signature accurately predicted MGMT promoter methylation in patients with astrocytomas, and achieved survival stratification for TMZ chemotherapy, thus providing a preoperative basis for individualised treatment planning.

Key Points
• Radiomics using magnetic resonance imaging can preoperatively perform satisfactory prediction of MGMT methylation in grade II-IV astrocytomas.
• Habitat-based radiomics can improve efficacy in predicting MGMT methylation status.
• Multi-sequence radiomics signature has the power to evaluate TMZ chemotherapy effect.

Keywords
Astrocytoma · Methylation · Prognosis · Diagnostic imaging · ROC curve
Abbreviations
ADC Apparent diffusion coefficient
AUC Area under the curve
DCA Decision curve analysis
GBM Glioblastoma
IDH Isocitrate dehydrogenase
MGMT Oxygen 6-methylguanine-DNA methyltransferase
MRI Magnetic resonance imaging
OS Overall survival
ROC Receiver operating characteristic
ROI Region of interest
T1-WI T1-weighted imaging
T2-FLAIR T2-weighted fluid-attenuated inversion recovery images
TMZ Temozolomide

Introduction
Astrocytoma is the most common type of glioma, and carries a poor prognosis [1, 2]. The average survival time ranges from 17 weeks to 3 years [2, 3]. Fortunately, a subgroup of grade II-IV astrocytoma patients with oxygen 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation show good responses to temozolomide (TMZ) chemotherapy and improved survival after treatment, which underscored the role of MGMT as a judicious molecular biomarker with a prognostic implication [4–7]. Preoperative identification of MGMT promoter methylation would be of great clinical significance in selecting potential patients benefiting from TMZ chemotherapy, thus assisting with planning the therapy regime. However, the standard approach for MGMT status confirmation requires a large tissue sample that is usually obtained through surgery. For patients with unresectable tumours, biopsy runs the risk of neurological deficits and can accordingly jeopardise the quality of life of the patient [8, 9]. Thus, there is an urgent need in clinical practice for preoperative and non-invasive prediction of MGMT promoter methylation in patients with astrocytomas.

In this study, we investigated the utility of a multi-sequence and multi-habitat MR radiomics signature as a preoperative and non-invasive biomarker of MGMT methylation prediction in patients with grade II–IV astrocytomas, and discuss the prognostic implications for survival stratification on TMZ chemotherapy response.

Materials and methods
Patients
This retrospective study was approved by the institutional review board. We reviewed 105 patients who were newly diagnosed with grade II–IV astrocytoma from October 2011 to March 2017. The inclusion and exclusion criteria are given in the Online Supplemental Appendix E1. The patient recruitment pathway is shown in Online Supplemental Fig. 1.

A total of 105 patients met the study criteria and were divided into a training dataset (31 December 2011 to 2 November 2015, n = 74) and a time-independent validation dataset (16 November 2015 to 21 March 2017, n = 31). Demographic and clinical data were acquired from medical reports, including sex, age, grade and radiological characteristics (Table 1).

For evaluation of the TMZ chemotherapy effect, the inclusion criteria were further expanded in the 105 patients: (1) patients receiving adjuvant treatment following surgery consisting of either (a) concomitant radiation plus TMZ followed by adjuvant TMZ or (b) TMZ; (2) overall survival (OS) was categorised according to death or survival exceeding the median survival of patients with each tumour grade (605 days for grade II, 398 days for grade III and 169 days for grade IV). Twenty-two patients met the inclusion criteria for the TMZ survival analysis. Demographic and clinical data of the 22 patients are shown in Table 2.
| Characteristic                        | Training cohort | Validation cohort | \( p \) (Inter) |
|--------------------------------------|-----------------|-------------------|-----------------|
|                                      | N=74            | N=31              |                 |
|                                      | MGMT (+)        | MGMT (-)          | MGMT (+)        | MGMT (-)          |                 |
|                                      |                | \( p \) (Intra)   | MGMT (+)        | MGMT (-)          | \( p \) (Intra) |
| Gender                               |                | 0.674             |                | 0.139             | 0.902           |
| Gender                               | Male           | 32 (43.2)         | 10 (13.5)       | 8 (25.8)          | 10 (32.3)       |
|                                      | Male           | 23 (31.1)         | 9 (12.2)        | 10 (32.3)         | 3 (9.7)         |
| Age, y                               | ≤52             | 32 (43.2)         | 8 (10.8)        | 13 (41.9)         | 8 (25.8)        |
|                                      | >52             | 23 (31.1)         | 11 (14.9)       | 5 (16.1)          | 5 (16.1)        |
| Grade                                |                | 0.258             |                | 0.701             | 0.195           |
| Grade                                | II              | 24 (32.4)         | 5 (6.8)         | 7 (22.6)          | 4 (12.9)        |
|                                      | III             | 22 (29.7)         | 8 (10.8)        | 9 (29.0)          | 5 (16.1)        |
|                                      | IV              | 9 (12.2)          | 6 (8.1)         | 2 (6.5)           | 4 (12.9)        |
| Tumour size                          |                | 0.508             |                | 1.000             | 0.073           |
| Tumour size                          | ≤6cm            | 27 (36.5)         | 11 (14.9)       | 6 (19.4)          | 4 (12.9)        |
|                                      | >6cm            | 28 (37.8)         | 8 (10.8)        | 12 (38.7)         | 9 (29.0)        |
| Tumour centre location               |                | 0.350             |                | 1.000             | 0.980           |
| Tumour centre location               | Left hemisphere | 25 (33.8)         | 11 (14.9)       | 9 (29.0)          | 6 (19.4)        |
|                                      | Right hemisphere| 30 (40.5)         | 8 (10.8)        | 9 (29.0)          | 7 (22.6)        |
| Frontal lobe                         |                | 0.674             |                | 0.013*            | 0.902           |
| Frontal lobe                         | Yes            | 32 (43.2)         | 10 (13.5)       | 14 (45.2)         | 4 (12.9)        |
|                                      | No             | 23 (31.1)         | 9 (12.2)        | 4 (12.9)          | 9 (29.0)        |
| Occipital lobe                       |                | 0.702             |                | 0.497             | 0.742           |
| Occipital lobe                       | Yes            | 5 (6.8)           | 3 (4.1)         | 2 (6.5)           | 0 (0.0)         |
|                                      | No             | 50 (67.6)         | 16 (21.6)       | 16 (51.6)         | 13 (41.9)       |
| Parietal lobe                        |                | 0.264             |                | 0.023*            | 0.116           |
| Parietal lobe                        | Yes            | 13 (17.6)         | 7 (9.5)         | 0 (0.0)           | 4 (12.9)        |
|                                      | No             | 42 (56.8)         | 12 (16.2)       | 18 (58.1)         | 9 (29.0)        |
| Temporal lobe                        |                | 0.706             |                | 0.710             | 0.728           |
| Temporal lobe                        | Yes            | 35 (47.3)         | 6 (8.1)         | 6 (19.4)          | 6 (19.4)        |
|                                      | No             | 20 (27.0)         | 13 (17.6)       | 12 (38.7)         | 7 (22.6)        |
| Insular lobe                         |                | 0.140             |                | 0.625             | 0.817           |
| Insular lobe                         | Yes            | 9 (12.2)          | 0 (0.0)         | 2 (6.5)           | 3 (9.7)         |
|                                      | No             | 46 (62.2)         | 19 (25.7)       | 16 (51.6)         | 10 (32.3)       |
| Involving cortex matter              |                | 0.635             |                | 1.000             | 0.742           |
| Involving cortex matter              | Yes            | 48 (64.9)         | 18 (24.3)       | 17 (54.8)         | 12 (38.7)       |
|                                      | No             | 7 (9.5)           | 1 (1.4)         | 1 (3.2)           | 1 (3.2)         |
| Involving deep white matter          |                | 0.910             |                | 0.497             | 0.238           |
| Involving deep white matter          | Yes            | 46 (62.2)         | 15 (20.3)       | 16 (51.6)         | 13 (41.9)       |
|                                      | No             | 9 (12.2)          | 4 (5.4)         | 2 (6.5)           | 0 (0.0)         |
| Involving pial matter                |                | 1.000             |                | 1.000             | 1.000           |
| Involving pial matter                | Yes            | 48 (64.9)         | 16 (21.6)       | 16 (51.6)         | 11 (35.5)       |
|                                      | No             | 7 (9.5)           | 3 (4.1)         | 2 (6.5)           | 2 (6.5)         |
| Involving ependymal membrane         |                | 0.555             |                | 1.000             | 0.600           |
| Involving ependymal membrane         | Yes            | 19 (25.7)         | 8 (10.8)        | 8 (25.8)          | 5 (16.1)        |
|                                      | No             | 36 (48.6)         | 11 (14.9)       | 10 (32.3)         | 8 (25.8)        |
| Tumour cross midline                 |                | 0.949             |                | 1.000             | 0.735           |
| Tumour cross midline                 | Yes            | 11 (14.9)         | 3 (4.1)         | 3 (9.7)           | 2 (6.5)         |
|                                      | No             | 44 (59.5)         | 16 (21.6)       | 15 (48.4)         | 11 (35.5)       |
The methylation status of the MGMT promoter was assessed using pyrosequencing analysis as described elsewhere [19]. Briefly, each tumour specimen was histologically investigated by macro-dissection to guarantee a tumour cell content of at least 80%. DNA was extracted using the Simplex OUP® FFPE DNA extraction kit (TIB, China) and quantified by spectrophotometry using a NanoDrop 2000 (Thermo Fisher Scientific, Loughborough, UK). Bisulphite modification of the extracted DNA was performed using the BisulFlash™ DNA modification kit (EpiGentek, Farmingdale, NY, USA). The PCR amplification and conditions are given in Online Supplemental Appendix E2.

### MRI acquisition

Preoperative MRI was performed with a 3.0-T scanner (Signa HDxt, GE Healthcare, USA) using an 8-channel array coil. The acquisition protocols for CE-T1-WI, T2-FLAIR and DWI are given in Online Supplemental Appendix E3.

### Table 1 (continued)

| Characteristic                  | Training cohort N=74 | Validation cohort N=31 | p (Intra) | p (Inter) |
|--------------------------------|----------------------|------------------------|-----------|-----------|
|                                | MGMT (+) | MGMT (-) |          | MGMT (+) | MGMT (-) |          |
| Oedema cross midline           |          |          | 1.000    |          |          | 1.000    |
| Yes                            | 12 (16.2)| 4 (5.4)  |          | 5 (16.1)| 4 (12.9) |          |
| No                             | 43 (58.1)| 15 (20.3)|          | 13 (41.9)| 9 (29.0) |          |
| Border                         |          |          | 0.171    |          |          | 0.099    |
| Well-defined                   | 14 (55.4)| 8 (10.8) |          | 2 (6.5) | 5 (16.1) |          |
| Ill-defined                    | 41 (18.9)| 11 (14.9)|          | 16 (51.6)| 8 (25.8) |          |
| Haemorrhage                    |          |          | 0.254    |          | 1.000    | 0.134    |
| Yes                            | 11 (14.9)| 1 (1.4)  |          | 5 (16.1)| 4 (12.9) |          |
| No                             | 44 (59.5)| 18 (24.3)|          | 13 (41.9)| 9 (29.0) |          |
| Cystic and necrosis            |          |          | 0.751    |          | 1        | 0.053    |
| No                             | 15 (20.3)| 5 (6.8)  |          | 7 (22.6)| 5 (16.1) |          |
| ≤25%                           | 21 (28.4)| 5 (6.8)  |          | 4 (12.9)| 3 (9.7)  |          |
| ≥50%                           | 11 (14.9)| 5 (6.8)  |          | 1 (3.2)| 1 (3.2)  |          |
| ≥50%                           | 8 (10.8) | 4 (5.4)  |          | 6 (19.4)| 4 (12.9) |          |
| Oedema degree                  |          |          | 0.011¹   |          | 0.275    | 0.563    |
| ≤1.6                           | 33 (44.6)| 5 (6.8)  |          | 10 (32.3)| 4 (12.9) |          |
| >1.6                           | 22 (29.7)| 14 (18.9)|          | 8 (25.8)| 9 (29.0) |          |
| Enhancement style              |          |          | 0.010²   |          | 0.034*  | 0.036²   |
| No                             | 15 (20.3)| 3 (4.1)  |          | 4 (19.4)| 0 (0.0)  |          |
| Ring enhancement               | 20 (27.0)| 15 (20.3)|          | 8 (25.8)| 8 (25.8) |          |
| Nodular enhancement            | 11 (14.9)| 0 (0.0)  |          | 6 (19.4)| 2 (6.5)  |          |
| Irregular reinforcement        | 9 (12.2) | 1 (1.4)  |          | 0 (0.0)| 3 (9.7)  |          |
| Enhancement degree             |          |          | 0.287    |          | 0.211    | 0.401    |
| No                             | 15 (20.3)| 3 (4.1)  |          | 4 (12.9)| 0 (0.0)  |          |
| Slight                         | 5 (6.8) | 0 (0.0)  |          | 2 (6.5)| 1 (3.2)  |          |
| Obvious                        | 35 (47.3)| 16 (21.6)|          | 12 (38.7)| 12 (38.7)|          |
| Signal characteristics         |          |          | 1.000    |          | 0.497    | 0.904    |
| Homogeneous                    | 5 (6.8) | 2 (2.7)  |          | 2 (6.5)| 0 (0.0)  |          |
| Heterogeneous                  | 50 (67.6)| 17 (23.0)|          | 16 (51.6)| 13 (41.9)|          |

MGMT(+): patients with oxygen 6-methylguanine-DNA methyltransferase (MGMT) methylation, MGMT(-): patients without MGMT methylation, p (Intra) the result of uni-variable analyses between methylated and unmethylated groups, p(Inter) significant difference between training and validation cohorts

Unless otherwise specified, data are numbers of patients, with percentages in parentheses

¹ p < 0.05
Demographic and clinical characteristic analysis

Differences between the training and validation cohorts and between the intra- MGMT methylated and unmethylated groups in terms of demographic and clinical factors were assessed with Pearson’s chi-square tests or Fisher’s exact tests for categorical variables and Student’s t-tests or Mann-Whitney U tests for continuous variables.

Sample size and power calculation

According to the thumb rule, the sample size needed to cover 10–15 observations per predictor variable to yield a stable estimate [20]. In our study, the maximum number of included features for radiomics signature construction was 5 (T2-FLAIR sequence on tumour area). Thus, the training dataset needed to include at least 50 patients. For the validation dataset power calculation, a sample of > 11 patients was required to provide 80% power and a type I error rate of 5% [21]. Our study cohort included 105 patients with 74 in the training dataset and 31 in the validation dataset, which met the sample size requirement.

Process of radiomics analysis

The radiomics analysis was structured into four parts: ROI segmentation, feature extraction, feature selection and model construction (Fig. 1). In brief, we performed a manual ROI with overlapped area by two radiologists (10 and 15 years of experience, respectively) on tumour and oedema habitats from T1-WI, T2-FLAIR and ADC maps, and the two radiologists were blinded to the final diagnosis and the MGMT methylation status. Examples of six typical segmentation cases according to grade and MGMT methylation status are shown in Fig. 2. The median ROI of each habitat and sequence is shown in Online Supplemental Table 3. A set of 3,051 imaging features was extracted including textural and non-textural features. Feature stability and reproducibility was estimated by Intra-class correlation coefficients and concordance correlation coefficients. Further feature selection was performed based on minimum redundancy and maximum relevance algorithm. Single radiomics signatures from each sequence and habitat, and a fusion radiomics signature were finally constructed using logistic regression modelling. A detailed description is given in Online Supplemental Appendix E4.

Clinical and radiological factors for MGMT prediction

Clinical factor analysis and ADC parameter calculation A univariate analysis was initially applied to select useful clinical factors (p < 0.1). Then, a forward selection (likelihood ratio) multi-variable analysis was performed to select clinical factors with p < 0.05. Additionally, we introduced ADC parameters (mean tumour ADC values and mean peritumoral oedema ADC values) associated with MGMT promoter methylation as reported in the literature [22]. Tumour and oedema ADC values were additionally integrated as a clinical model by logistic regression based on the training cohort.

Combined model with radiomics signature, clinical factor, and ADC values To achieve a holistic information-gathered network, we generated a comprehensive model including the fusion radiomics signature, the selected clinical factor (oedema degree), and two ADC values (the tumour and oedema areas). Considering a correlation between the radiomics signature and other factors as well as the model complexity, we adopted the Akaike information criterion (AIC) to select optimal incorporated factors and used logistic regression modelling to perform model construction.

Performance evaluation

Receiver operating characteristic (ROC) curves were plotted and area under the curve (AUC), specificity and sensitivity

| Table 2 Clinical characteristics and MGMT predicted outcome for patients with TMZ chemotherapy |
|-----------------------------------------------|------------------|
| Characteristic                                | Patients N=22   |
| Gender                                        |                  |
| Male                                          | 13 (59.1)       |
| Female                                        | 9 (40.9)        |
| Age, y                                        |                  |
| ≤49                                           | 12 (54.5)       |
| >49                                           | 10 (45.5)       |
| Grade                                         |                  |
| II                                            | 6 (27.3)        |
| III                                           | 11 (50.0)       |
| IV                                            | 5 (22.7)        |
| MGMT                                          |                  |
| +                                             | 17 (77.2)       |
| –                                             | 5 (22.8)        |
| Predicted MGMT                                |                  |
| MGMT(+)                                       | 14 (82.3)       |
| MGMT(–)                                       | 3 (17.7)        |

MGMT(+) patients with oxygen 6-methylguanine-DNA methyltransferase (MGMT) methylation, MGMT(–) patients without MGMT methylation

Unless otherwise specified, data are numbers of patients, with percentages in parentheses

The average age was 49 years, thus we divided patients into an age ≤ 49 years group and an age > 49 years group

Demographic and clinical characteristic analysis

Differences between the training and validation cohorts and between the intra- MGMT methylated and unmethylated groups in terms of demographic and clinical factors were assessed with Pearson’s chi-square tests or Fisher’s exact tests for categorical variables and Student’s t-tests or Mann-Whitney U tests for continuous variables.

Sample size and power calculation

According to the thumb rule, the sample size needed to cover 10–15 observations per predictor variable to yield a stable estimate [20]. In our study, the maximum number of included features for radiomics signature construction was 5 (T2-FLAIR sequence on tumour area). Thus, the training dataset needed to include at least 50 patients. For the validation dataset power calculation, a sample of > 11 patients was required to provide 80% power and a type I error rate of 5% [21]. Our study cohort included 105 patients with 74 in the training dataset and 31 in the validation dataset, which met the sample size requirement.
were calculated for the fusion radiomics signature, selected clinical factor and ADC parameter. We further performed stratification analysis for the fusion radiomics signature by grouping the cohorts according to age, gender and grade. We chose decision curve analysis (DCA) to estimate the clinical usefulness of the developed fusion radiomics signature and used the Delong test to explore whether the fusion radiomics signature performed better than the traditional clinical model and ADC parameter.

Prognostic value analysis

A Kaplan-Meier curve was plotted based on the fusion radiomics signature in order to stratify the OS in patients treated with adjuvant TMZ chemotherapy. The log-rank test was used to determine whether there were statistical differences between the two survival groups.

Statistical analysis

We performed the statistical analysis with PASW Statistics, version 18.0 (SPSS Inc., Chicago, IL, USA) and R software, version 3.4.1 (www.R-project.org). The threshold for statistical significance was a two-sided $p < 0.05$.

Results

Patient demographic data, clinical characteristics and molecular subtypes

The baseline characteristics of the patients are shown in Table 1. There were no differences between the training and validation cohorts in terms of demographic or clinical characteristics ($p = 0.053–1.000$).

In total, we included 73 (69.5%) patients with MGMT promoter methylation and 32 (30.5%) patients without MGMT promoter methylation. No significant difference was shown for the MGMT methylation status distribution in the training and validation cohorts ($p = 0.156$).

Feature stability and reproducibility estimation

The statistical results of feature numbers after stability and reproducibility analysis are shown in Online Supplemental Fig. 2.
Features extracted from tumour habitats exhibited statistically better performance than those extracted from peritumoral oedema habitats (reproducibility, \( p < 0.001 \); stability, \( p < 0.001 \)).

**Single radiomics signatures formula and evaluation**

The selected features and integration formulas for single radiomics signatures derived from each sequence and habitat are shown in Online Supplemental Table 1 and Appendix E5, respectively. A detailed explanation of each selected feature is shown in Online Supplemental Table 2. Single radiomics signatures from T1-WI-tumour, T1-WI-oedema, T2-FLAIR-tumour, and T2-FLAIR-oedema were verified as eligible radiomics signatures with AUCs > 0.7 in both the training and validation cohorts (Table 3). These four single radiomics signatures all showed significant differences (\( p < 0.05 \)) in the.

### Table 3 Diagnostic performance of single radiomics signatures, fusion radiomics signature, clinical factors and ADC values

| Models          | Training cohort N=74 | Validation cohort N=31 |
|-----------------|----------------------|------------------------|
|                 | Sensitivity | Specificity | Accuracy | AUC (95% CI) | Sensitivity | Specificity | Accuracy | AUC (95% CI) |
| Tumour T1       | 0.778       | 0.691       | 0.716    | 0.706 (0.567–0.845) | 0.615       | 0.667       | 0.645    | 0.739 (0.558–0.921) |
| Tumour T2       | 0.947       | 0.782       | 0.824    | 0.916 (0.852–0.979) | 0.538       | 0.889       | 0.742    | 0.701 (0.494–0.908) |
| Tumour ADC      | 0.895       | 0.655       | 0.716    | 0.815 (0.714–0.917) | 0.692       | 0.389       | 0.516    | 0.590 (0.381–0.799) |
| Oedema T1       | 0.632       | 0.782       | 0.743    | 0.738 (0.601–0.875) | 0.615       | 0.667       | 0.645    | 0.709 (0.519–0.900) |
| Oedema T2       | 0.684       | 0.727       | 0.716    | 0.778 (0.654–0.902) | 0.615       | 0.778       | 0.710    | 0.752 (0.567–0.937) |
| Oedema ADC      | 0.632       | 0.782       | 0.743    | 0.678 (0.534–0.822) | 0.615       | 0.889       | 0.774    | 0.816 (0.667–0.965) |
| Fusion radiomics | 0.872       | 0.842       | 0.865    | 0.925 (0.861–0.989) | 0.944       | 0.539       | 0.774    | 0.902 (0.785–1.000) |
| Clinical factors| 0.737       | 0.600       | 0.6351   | 0.668 (0.548–0.789) | 0.692       | 0.556       | 0.613    | 0.624 (0.448–0.800) |
| ADC values      | 0.632       | 0.691       | 0.676    | 0.649 (0.511–0.787) | 0.615       | 0.722       | 0.677    | 0.603 (0.382–0.823) |

95% CI 95% confidence interval, AUC area under curve, T1 contrast-enhanced T1-weighted sequence, T2 T2-FLAIR sequence
MGMT methylated and unmethylated groups in both the training and the validation cohorts. Boxplots describing the distribution of the four radiomics signatures in the MGMT methylated and unmethylated groups are shown in Online Supplemental Fig. 3. However, neither ADC-tumour nor ADC-oedema performed with satisfactory results for MGMT identification. ADC-tumour did not perform well in the validation cohort (AUC = 0.590) while ADC-oedema did not perform well in the training cohort (AUC = 0.678). Detailed predictive indicators (AUC, accuracy, sensitivity and specificity) of each single radiomics signature are shown in Table 3.

**Fusion radiomics signature formula and evaluation**

The fusion radiomics signature combining the four single radiomics signatures was constructed with a Rad-score calculated as follows:

\[
Rad\text{-}score\text{(fusion)} = -6.785 - 1.026 \times \text{Signature}_{\text{Oedema-T1}} + 3.950 \times \text{Signature}_{\text{Oedema-T2}} + 2.907 \times \text{Signature}_{\text{Tumour-T1}} + 5.427 \times \text{Signature}_{\text{Tumour-T2}}
\]

The optimum cut-off value of the fusion radiomics was 1.077 as per the Youden index. Patients were divided into predicted MGMT methylated (Rad-score ≥ 1.077) and unmethylated groups (Rad-score < 1.077) based on fusion Rad-scores.

Barplots depicting the classification performance of the fusion signature in the training and validation cohorts are shown in Fig. 3. The fusion radiomics signature achieved optimal AUC values of 0.925 and 0.902 in the training and validation cohorts, respectively. Detailed predictive indicators (accuracy, sensitivity and specificity) of the fusion radiomics signature are shown in Table 3.

**Clinical model and ADC parameter evaluation**

Only oedema degree was significantly different between the MGMT methylated and unmethylated groups in the training cohort (p = 0.0015). The AUCs of this clinical factor were 0.668 and 0.624 in the training and validation cohorts, respectively. The ADC parameter achieved AUC values of 0.649 and 0.603 in the training and validation cohorts, respectively. Detailed predictive indicators (sensitivity and specificity) of the clinical model and ADC parameter are shown in Table 3.

**Performance comparison**

The fusion radiomics signature achieved the highest AUC among the three models. The Delong test showed a significant difference between the fusion radiomics signature and the clinical model (p = 0.008 and 0.011), and between the fusion radiomics signature and ADC parameter (p = 0.003 and 0.027) in the training and validation cohorts, respectively.

**Combined model construction and evaluation**

During the combined model construction process, the AIC value was minimum when only taking the fusion radiomics
Table 4 Stratification analysis of the fusion radiomics signature on training and validation cohorts

| Subgroups | MGMT (+) | MGMT (-) |
|-----------|----------|----------|
|            | AUC (95% CI) | p-value | AUC (95% CI) | p-value |
| **Age, y** | 52 | 2.79 (2.07–3.52) | <0.001 | 2.85 (2.64–3.13) | <0.001 |
| >52        | 2.74 (2.13–3.32) | <0.001 | 2.85 (2.64–3.13) | <0.001 |
| **Gender** | Male | 2.74 (2.13–3.32) | <0.001 | 2.93 (2.72–3.13) | <0.001 |
| Female     | 2.58 (2.07–3.17) | <0.001 | 2.55 (2.27–3.17) | <0.001 |
| **Grade**  | II | 2.89 (2.29–3.55) | <0.001 | 3.15 (2.74–3.50) | <0.001 |
| III        | 2.69 (2.09–3.26) | <0.001 | 2.55 (2.27–3.17) | <0.001 |
| IV         | 2.40 (1.82–3.08) | <0.001 | 2.55 (2.27–3.17) | <0.001 |

* p-value < 0.05 indicates significant difference in the median radiomics score between the MGMT(+) and MGMT(-) groups.

In previous work, Xi et al. showed that a radiomics signature derived from T1-WI, T2-WI and enhanced T1-WI was a potential imaging marker for the prediction of MGMT methylation or all patients had MGMT methylation (Fig. 4b).
promoter methylation in GBMs, with prediction accuracy of 86.59% in the training cohort and 80% in the validation cohort [30]. However, MGMT methylated patients not only behaved well in GBM, but also presented with prolonged survival in lower-grade astrocytomas [4, 31]. Our study used an expanded cohort that included grade II-IV astrocytomas, and performed with superior AUCs of 0.926 and 0.902 in the training and validation datasets, respectively. Notably, our proposed fusion radiomics signature has the power to distinguish MGMT methylation in separate grade II, III and IV (GBM) cohorts, as well as in a grade II-IV cohort. It can predict MGMT methylation status directly without the need for a pathological grading prerequisite. Considering that the most significant advantage of radiomics is its non-invasive characteristics, pre-knowledge of grading that requires biopsy critically limits the clinical application of radiomics, while our results showed great advances on the previous study with improved high accuracy. This finding will strongly promote radiomics application in clinical practice.

Furthermore, we also investigated whether a combined model integrating clinical factors, radiological factors and fusion radiomics signature would outperform the signature alone. However, adding oedema degree and ADC values to the fusion radiomics signature caused minor deterioration rather than improvement in prediction performance. This indicated that adding clinical and radiological factors to the radiomics signature increased the complexity without increasing the prediction accuracy. The oedema degree and ADC values, as kinds of semi-quantitative clinical and quantitative radiological factors, partially depended on the subjective judgement of radiologists (sometimes with strong reservations), and their prediction performance were poorer compared with the radiomics signature. Thus when incorporating these factors into the radiomics signature, there was no additional positive effect on the improvement of the prediction performance, but rather an increased complexity of the prediction model. Additionally, even though it was reported that ADC values were correlated with MGMT promoter methylation and prognosis in GBM [22, 32, 33], our results indicated that radiomic features extracted from T1-CE and T2-FLAIR sequences performed better than those extracted from the ADC sequence. A potential reason for this observation is the relatively poor imaging resolution of ADC, which limited the stability and robustness of the derived radiomics features.

MGMT promoter methylation has been shown to be associated with longer OS, [34]. In our study, MGMT promoter methylation status successfully stratified astrocytoma patients treated with adjuvant TMZ chemotherapy into two groups with significant prognostic differences, consistent with previous research [6]. We also validated the proposed fusion radiomics signature for assessing TMZ chemotherapy effect. Using the cut-off value of the fusion Rad-score, patients with positive radiomics scores after TMZ chemotherapy had

Fig. 4 (a) Kaplan-Meier curve verifying the prognostic value of the fusion radiomics signature. Patients were successfully divided into high-risk (red line) and low-risk (green line) groups ($p = 0.0308$). (b) Decision curve analysis for the fusion radiomics signature on the overall cohort. The y-axis represents the net benefit and the x-axis represents the threshold probability. The threshold probability of the decision curve is 26% and the corresponding net benefit is 0.441. * $p < 0.05$
significantly longer OS than patients with negative scores ($p = 0.03$), revealing another possible clinical application of this genetic prediction tool.

The present study had several limitations. First, our model was trained and validated using retrospective data collected from a single institution. A large-scale prospective and multicentre validation cohort collection is currently underway. Second, our radiomics analysis only predicted MGMT promoter methylation prediction from T1-CE, T2-FLAIR and ADC map images, which are the most common structural MR images. Additional scanning sequences such as dynamic susceptibility contrast, susceptibility-weighted imaging and diffusion kurtosis imaging will be included in future studies to further improve predictive performance. Third, the relationship between imaging features and critical molecular markers such as IDH and 1p19q should also be studied in future research. Finally, the manual segmentation method used to delineate ROIs in this study (tumour and oedema) was quite time consuming. Semi-automatic or deep learning-based automatic segmentation methods may enhance the objectivity of our method and promote the seamless integration of this technology into clinical application.

In conclusion, habitat-based MRI radiomics could provide a non-invasive imaging strategy for the preoperative prediction of MGMT promoter methylation in patients with grade II–IV astrocytomas, and has prognostic implications for TMZ chemotherapy, which may serve as a tool for guiding individualised treatment decision making.

**Methodology**
- retrospective
- diagnostic or prognostic study
- performed at one institution

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507
2. Walker DG, Kaye AH (2001) Diagnosis and management of astrocytomas, oligodendrogliomas and mixed gliomas: a review. Australas Radiol 45(4):472–482
3. DeAngelis LM (2001) Brain tumors. N Engl J Med 344(2):114–123
4. Everhard S, Kaloshi G, Cricière E et al (2006) MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60(6):740–743
5. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
6. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003
7. Cairncross G, Wang M, Shaw E et al (2012) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31(3):337–343
8. Sanai N, Martino J, Berger MS (2012) Morbidity profile following aggressive resection of parietal lobe gliomas. J Neurosurg 116(6):1182–1186
9. Tate MC, Kim CY, Chang EF et al (2011) Assessment of morbidity following resection of cingulate gyrus gliomas. J Neurosurg 114(3):640–647
10. Henson JW, Gaviani P, Gonzalez RG (2005) MRI in treatment of adult gliomas. Lancet Oncol 6(3):167–175
11. Eoli M, Menghi F, Bruzzone MG et al (2007) Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res 13(9):2606–2613
12. Drabycz S, Roldán G, de Robles P et al (2010) An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage 49(2):1398–1405
13. Kumar V, Gu Y, Basu S et al (2012) Radiomics: the process and the challenges. Magn Reson Imaging 30(9):1234–1248
14. Lambin P, Rios-Velazquez E, Leijenaar R et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48(4):441–446
15. Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: Images are more than pictures, they are data. Radiology 278(2):563–577
16. Brown R, Zlatescu M, Sibben A et al (2008) The use of magnetic resonance imaging to non-invasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 14(8):2357–2362
17. Yu J, Shi Z, Lian Y et al (2017) Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma. Eur Radiol 27(8):3509–3522
18. Zhou M, Hall L, Goldgof D et al (2014) Radiologically defined ecological dynamics and clinical outcomes in glioblastoma multiforme: preliminary results. Transl Oncol 7(1):5–13
19. Dunn J, Baborie A, Alam F et al (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101(1):124–131
20. Helmreich JE (2016) Regression modeling strategies with applications to linear models, logistic and ordinal regression and survival analysis (2nd edition). J Stat Softw. 70 (Book Review 2)
21. Bock J (2001) Power and sample size calculations. Springer, New York 11(4):309-333
22. Romano A, Calabria LF, Tavanti F et al (2013) Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status. Eur Radiol 23(2):513–520
23. Wick W, Weller M, van den Bent M et al (2014) MGMT testing-The challenges for biomarker based glioma treatment. Nat Rev Neurol 10(7):372–385
24. Ellingson BM, Cloughesy TF, Pope WB et al (2012) Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage 59(2):908–916
25. Kickingereder P, Burth S, Wick A et al (2016) Radiomic profiling of glioblastoma: identifying an imaging predictor of patient survival with improved performance over established clinical and radiologic risk models. Radiology 280(3):880–889
26. Kickingereder P, Neuberger U, Bonekamp D et al (2017) Radiomic subtyping improves disease stratification beyond key molecular, clinical and standard imaging characteristics in patients with glioblastoma. Neuro Oncol. https://doi.org/10.1093/neo/neox188
27. Huang Y, Liu Z, He L et al (2016) Radiomics signature: A potential biomarker for the prediction of disease-free survival in early-stage (I or II) non-small cell lung cancer. Radiology 281(3):947–957
28. Rutman AM, Kuo MD (2009) Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol 70(2):232–241
29. Kuo MD, Gollub J, Sirlin CB et al (2007) Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol 18(7):821–831
30. Xi YB, Guo F, Xu ZL et al (2017) Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma. J Magn Reson Imaging. https://doi.org/10.1002/jmri.25860
31. Minniti G, Scaringi C, Arcella A et al (2014) IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. J Neurooncol 118(2):377–383
32. Rundle-Thiele D, Day B, Stringer B et al (2015) Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method. J Med Radiat Sci 62(2):92–98
33. Yoon RG, Kim HS, Paik W et al (2016) Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation. Eur Radiol 27(1):255–266
34. Wick W, Platten M, Meisner C et al (2012) Chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13(7):707–715